Plant Comparison

Bay-leaf willowherb vs Chaga

A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant ABay-leaf willowherbEpilobium parviflorumOnagraceaeFull monograph →
Plant BChagaInonotus obliquusHymenochaetaceaeFull monograph →

At a glance

Bay-leaf willowherb and Chaga: they share 6 indicated uses (arthritis / joint pain, cancer (anticancer research), infection (general), …); 4 pharmacological actions in common.

Bay-leaf willowherbChaga
Constituents33
Pharmacological actions410
Indicated uses911
Safety notes22
Cited sources1541
Indicated uses
Only Bay-leaf willowherb
Prostate supportUrinary supportUrinary tract infection (UTI)
Shared (6)
Arthritis / joint painCancer (anticancer research)Infection (general)Inflammation (general)Skin irritationWounds
Only Chaga
Cold & fluImmune supportMetabolic supportCognitive functionCardiovascular / heart health
Pharmacological actions
Only Bay-leaf willowherb
none
Shared (4)
Anti-inflammatoryAnticancer (preclinical)AntimicrobialAntioxidant
Only Chaga
Immunomodulator / immune supportNephroprotective (kidney support)Neuroprotective / cognition supportAntidiabetic (blood-sugar lowering)Hepatoprotective (liver support)Lipid-lowering

Evidence face-off — shared uses

ConditionBay-leaf willowherbChagaVerdict
Arthritis / joint pain1/101/10Comparable evidence
Cancer (anticancer research)2/102/10Comparable evidence
Infection (general)1/101/10Comparable evidence
Inflammation (general)1/101/10Comparable evidence
Skin irritation1/101/10Comparable evidence
Wounds1/101/10Comparable evidence

Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Macrocyclic ellagitannins (notably oenothein B)[4, 5, 6, 7, 8, 13]

Characteristic Epilobium polyphenols underlying the anti-inflammatory and prostate activity; a genus review identifies oenothein B as the dominant constituent and likely driver of the antimicrobial, anti-inflammatory, anti-proliferative and antioxidant effects.

TanninsPhenolic compounds
Flavonoids (myricetin and quercetin glycosides)[11, 13]

Antioxidant constituents.

FlavonoidsGlycosidesQuercetin
Plant sterols (beta-sitosterol)[13]

Sterols associated with benign prostatic hyperplasia support.

Phytosterols
Melanin-rich pigments and betulinic acid derivatives[1]

Chaga's dark colour comes from melanin-like pigments; it also concentrates betulinic-acid-type triterpenes absorbed from its birch host, associated with antioxidant and anticancer research interest.

Polysaccharides (beta-glucans)[4]

Immunomodulatory polysaccharides contributing to the traditional tonic and immune-support use.

Polysaccharides
Phenolic compounds[4]

Antioxidant phenolics contributing to chaga's free-radical-scavenging activity.

Phenolic compounds

Pharmacological Actions

Anti-inflammatory[1, 3, 4, 6, 10, 13]

Anti-inflammatory (inhibits COX-1 and COX-2 prostaglandin synthesis)

Anticancer (preclinical)[3]
Antimicrobial[13]

Antibacterial, including against Escherichia coli (urinary support)

Antioxidant[1, 6, 9, 10, 11, 13]

Antioxidant (hydroxyl-radical scavenging)

Anti-inflammatory[4, 5, 9, 13, 15, 19, 27, 30, 38, 39, 40]
Anticancer (preclinical)[15, 17, 21, 22, 26, 28, 31, 38]
Antimicrobial[38, 39, 40]
Antioxidant[8, 10, 12, 29, 35, 38, 39, 40]
Immunomodulator / immune support[2, 4, 7, 14, 16, 19, 26, 32, 37, 38, 39, 40]
Nephroprotective (kidney support)[20]
Neuroprotective / cognition support[24, 35]
Antidiabetic (blood-sugar lowering)[25, 31, 34, 36]
Hepatoprotective (liver support)[28]
Lipid-lowering[33, 36]

Traditional & Indicated Uses

Arthritis / joint pain[13]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Cancer (anticancer research)[3]Traditional · 2/10

inferred from anticancer action

Evidence: 2
Label: Cancer (anticancer research)
Infection (general)[13]Traditional · 1/10

inferred from antimicrobial action

Evidence: 1
Label: Infection (general)
Inflammation (general)[13]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Inflammation (general)
Prostate support[4, 13, 15]Moderate · 5/10

Supports lower urinary tract symptoms of benign prostatic hyperplasia (prostate support) - a genus Epilobium review notes traditional BPH use attributed mainly to oenothein B, though clinical evidence is not yet conclusive

Evidence: 5
Label: Prostate support
Skin irritation[13]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation
Urinary support[4, 13, 15]Moderate · 5/10

Antibacterial, including against Escherichia coli (urinary support); Supports lower urinary tract symptoms of benign prostatic hyperplasia (prostate support) - a genus Epilobium review notes traditional BPH use attributed mainly to oenothein B, though clinical evidence is not yet conclusive

Evidence: 5
Label: Urinary support
Urinary tract infection (UTI)[4, 13, 15]Moderate · 5/10

Supports lower urinary tract symptoms of benign prostatic hyperplasia (prostate support) - a genus Epilobium review notes traditional BPH use attributed mainly to oenothein B, though clinical evidence is not yet conclusive

Evidence: 5
Label: Urinary tract infection (UTI)
Wounds[13]Traditional · 1/10

inferred from antimicrobial action

Evidence: 1
Label: Wounds
Arthritis / joint pain[38, 39, 40]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Cancer (anticancer research)[15, 21, 38]Traditional · 2/10

inferred from anticancer action

Evidence: 2
Label: Cancer (anticancer research)
Cold & flu[38, 39, 40]Traditional · 1/10

inferred from immunomodulator action

Evidence: 1
Label: Cold & flu
Immune support[14, 38, 39, 40]Traditional · 2/10
Evidence: 2
Label: Immune support
Infection (general)[38, 39, 40]Traditional · 1/10

inferred from antimicrobial action

Evidence: 1
Label: Infection (general)
Inflammation (general)[38, 39, 40]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Inflammation (general)
Metabolic support[38, 39, 40]Traditional · 1/10
Evidence: 1
Label: Metabolic support
Skin irritation[38, 39, 40]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation
Wounds[38, 39, 40]Traditional · 1/10

inferred from antimicrobial action

Evidence: 1
Label: Wounds
Cognitive function[24, 35]Traditional · 2/10

Chaga-derived 3,4-DHBA protected against Parkinson's-related neurotoxicity (preclinical).

Evidence: 2
Label: Cognitive function
Cardiovascular / heart health[33]Traditional · 2/10

Chaga polysaccharide lowered lipids in vivo and in vitro.

Evidence: 2
Label: Cardiovascular / heart health

Safety, Cautions & Contraindications

Safety note[15]Info

Lower urinary tract / prostate symptoms must be medically assessed first to exclude prostate cancer; willowherb is a supportive measure, not a substitute for diagnosis and treatment.

Safety note[15]Info

Well tolerated over three months in clinical use; longer-term safety data are limited.

Safety note[38, 39, 40]Caution

Autoimmune conditions: Chaga can stimulate parts of the immune system—people with autoimmune diseases should be cautious.Blood thinners: Chaga contains compounds that may affect clotting—avoid large doses if on anticoagulants.Blood sugar meds: May slightly lower glucose—monitor if taking diabetes medication.Pregnancy & breastfeeding: Limited safety data—best avoided unless guided by a professional.Quality matters: Wild-harvested Chaga can accumulate heavy metals from trees and soil—source from reputable suppliers.

Safety note[38, 39, 40, 41]Info

Duke (2002) does not include a dedicated entry for chaga (Inonotus obliquus) in the Handbook of Medicinal Herbs, Second Edition, as this medicinal fungus was not widely documented in Western herbal literature at that time (Duke, 2002).

External Ids

Gbif: 3189157
Wikidata: Q159094
Gbif: 2521089
Wikidata: Q1956937

Botanical Description

Slender, softly hairy perennial herb with narrow, lance-shaped leaves and small, four-petalled, pale pink to lilac flowers with a notched tip, borne singly in the upper leaf axils. After flowering, long, narrow seed pods split to release cottony-tufted seeds, typical of the willowherb genus.[13]

Height: 20-60 cm
Habit: Slender, softly hairy, erect perennial herb
Leaves: Narrow, lance-shaped, softly hairy
Flowers: Small, four-petalled, pale pink to lilac, notched, borne singly in upper leaf axils
Stem: Slender, softly hairy, erect
Root: Fibrous root with short rhizome
Fruit: Long, narrow seed pod releasing cottony-tufted seeds
Flowering Period: June-September

Parasitic wood-decay fungus (not a true plant) that grows almost entirely inside the trunk of living birch trees, visible externally only as a hard, black, cracked, charcoal-like mass (a sclerotium, sometimes called a 'conk') erupting through the bark. Unlike typical mushrooms, chaga has no true cap, gills or stem; its fertile spore-producing surface develops later, hidden beneath the bark after the tree dies.[1]

Height: External mass 10-40 cm
Habit: Parasitic wood-decay fungus, growing mostly inside the host tree
Leaves: Not applicable (fungus)
Flowers: Not applicable (fungus); reproduces by spores
Stem: No true cap-and-stem structure; visible only as a hard black external mass (sclerotium)
Root: Fungal mycelium spreading through the living wood of the host tree
Fruit: Fertile spore-producing layer develops hidden beneath the bark, typically after the host tree dies
Flowering Period: The visible black mass persists and grows for years; not a seasonal fruiting body

Habitat

Grows in damp meadows, ditches, streamsides and waste ground on moist soils; native to Europe and temperate Asia.[13]

Grows almost exclusively as a parasite on living birch trees in cold, northern temperate and boreal forests of Europe, Russia, North America and Asia.[1]

Harvesting

The flowering aerial parts are cut in summer while in flower, and dried in a warm, shaded, airy place.[13]

Parts: Aerial parts (herb)
Season: Summer flowering period

The hard black external mass (conk) is chopped or broken away from the living birch trunk, ideally without killing the tree, then dried and broken into pieces or ground for use; sustainable harvesting (leaving part of the conk to regrow) is recommended given the fungus's slow growth.

Parts: Mycelium, Whole Plant

Traditional Uses

Small-flowered willowherb, along with related Epilobium species, has a Central European folk tradition as a supportive remedy for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) and prostatitis, and as an antimicrobial and anti-inflammatory herb for minor infections; the traditional prostate-support use is attributed mainly to its oenothein B content, though robust clinical evidence remains limited.[13]

Chaga has a long traditional use in Russian, Siberian, Baltic and Scandinavian folk medicine as a tonic remedy for digestive complaints, immune support and general vitality, traditionally taken as a dark, tea-like decoction; this traditional tonic reputation is now studied for its antioxidant, immunomodulatory and anti-inflammatory properties.[1, 4]

Preparations

Infusion[13]

Dried flowering herb infused in hot water as a traditional urinary and prostate-support tea.

Decoction[1]

Chunks of the dried black conk simmered gently in water for an extended period, producing a dark, tea-like traditional tonic.

Standardised extract[4]

Extract standardised to polysaccharide or polyphenol content, taken as capsules or powder.

Dosage

Infusion[14]

The EU herbal monograph gives 1.5-2.0 g of the comminuted herb in 250 mL of boiling water as an infusion, twice daily, in adults and elderly; long-term use is possible. Lower urinary tract or prostate symptoms should always be medically assessed first, and the monograph directs that a doctor be consulted if fever, spasms, blood in the urine, painful urination or urinary retention occur. Educational reference only, not a prescription.

Not documented

References

REF-0803, REF-0804, REF-0805, REF-0618, REF-2297, REF-2298, REF-2299, REF-2300, REF-2301, REF-2302, REF-2303, REF-2304
REF-0848, REF-0849, REF-0850, REF-2195, REF-2196, REF-2197, REF-2198, REF-2199, REF-2200, REF-2201, REF-2202, REF-2203, REF-2204, REF-2969, REF-2970, REF-2971, REF-2972, REF-2973, REF-2974, REF-2975, REF-2976, REF-2977, REF-2978, REF-2979, REF-2980, REF-2981, REF-2982, REF-2983, REF-2984, REF-2985, REF-2986, REF-2987, REF-2988, REF-2989, REF-2990, REF-2991, REF-2992

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07
Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

References & Sources

  1. Vitalone, A. and Allkanjari, O (2018) 'Epilobium spp: Pharmacology and Phytochemistry', Phytotherapy Research, 32(7), pp. 1229-1240. doi:10.1002/ptr.6072 Traditional / reference
    https://doi.org/10.1002/ptr.6072
  2. Cicero, A.F.G., Allkanjari, O., Busetto, G.M., Cai, T. et al (2019) 'Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer', Archivio Italiano di Urologia e Andrologia, 91(3), pp. 139-152. doi:10.4081/aiua.2019.3.139 Traditional / reference
    https://doi.org/10.4081/aiua.2019.3.139
  3. Vlase, A.M., Toiu, A., Gligor, O., Muntean, D. et al (2024) 'Investigation of Epilobium hirsutum L. Optimized Extract's Anti-Inflammatory and Antitumor Potential', Plants (Basel), 13(2), pp. 198. doi:10.3390/plants13020198 Preclinical
    https://doi.org/10.3390/plants13020198
  4. Granica, S., Piwowarski, J.P., Czerwinska, M.E. and Kiss, A.K (2014) 'Phytochemistry, pharmacology and traditional uses of different Epilobium species (Onagraceae): a review', Journal of Ethnopharmacology, pp. 316--346. doi:10.1016/j.jep.2014.08.036 Traditional / reference
    https://doi.org/10.1016/j.jep.2014.08.036
  5. Ramstead, A.G., Schepetkin, I.A., Quinn, M.T. and Jutila, M.A (2012) 'Oenothein B, a cyclic dimeric ellagitannin isolated from Epilobium angustifolium, enhances IFN-gamma production by lymphocytes', PLoS One, 7(11), pp. e50546. doi:10.1371/journal.pone.0050546 Preclinical
    https://doi.org/10.1371/journal.pone.0050546
  6. Kiss, A.K., Bazylko, A., Filipek, A., Granica, S., Jaszewska, E., Kiarszys, U., Kosmider, A. and Piwowarski, J (2011) 'Oenothein B's contribution to the anti-inflammatory and antioxidant activity of Epilobium sp', Phytomedicine, 18(7), pp. 557-560. doi:10.1016/j.phymed.2010.10.016 Preclinical
    https://doi.org/10.1016/j.phymed.2010.10.016
  7. Schepetkin, I.A., Kirpotina, L.N., Jakiw, L., Khlebnikov, A.I., Blaskovich, C.L., Jutila, M.A. and Quinn, M.T (2009) 'Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium', Journal of Immunology, 183(10), pp. 6754-6766. doi:10.4049/jimmunol.0901827 Preclinical
    https://doi.org/10.4049/jimmunol.0901827
  8. Ducrey, B., Marston, A., Gohring, S., Hartmann, R.W. and Hostettmann, K (1997) 'Inhibition of 5-alpha-reductase and aromatase by the ellagitannins oenothein A and oenothein B from Epilobium species', Planta Medica, 63(2), pp. 111-114. doi:10.1055/s-2006-957624 Preclinical
    https://doi.org/10.1055/s-2006-957624
  9. Schepetkin, I.A., Ramstead, A.G., Kirpotina, L.N., Voyich, J.M., Jutila, M.A. and Quinn, M.T (2016) 'Therapeutic potential of polyphenols from Epilobium angustifolium (fireweed)', Phytotherapy Research, 30(8), pp. 1287-1297. doi:10.1002/ptr.5648 Meta-analysis / review
    https://doi.org/10.1002/ptr.5648
  10. Merighi, S., Travagli, A., Tedeschi, P., Marchetti, N. and Gessi, S (2021) 'Antioxidant and anti-inflammatory effects of Epilobium parviflorum, Melilotus officinalis and Cardiospermum halicacabum plant extracts in macrophage and microglial cells', Cells, 10(10), pp. 2691. doi:10.3390/cells10102691 Preclinical
    https://doi.org/10.3390/cells10102691
  11. Hevesi Toth, B., Blazics, B. and Kery, A (2009) 'Polyphenol composition and antioxidant capacity of Epilobium species', Journal of Pharmaceutical and Biomedical Analysis, 49(1), pp. 26-31. doi:10.1016/j.jpba.2008.09.047 Preclinical
    https://doi.org/10.1016/j.jpba.2008.09.047
  12. Vitalone, A., McColl, J., Thome, D., Costa, L.G. and Tita, B (2003) 'Characterization of the effect of Epilobium extracts on human cell proliferation', Pharmacology, 69(2), pp. 79-87. doi:10.1159/000072360 Preclinical
    https://doi.org/10.1159/000072360
  13. Steenkamp, V., Gouws, M.C., Gulumian, M., Elgorashi, E.E. and van Staden, J (2005) 'Studies on antibacterial, anti-inflammatory and antioxidant activity of herbal remedies used in the treatment of benign prostatic hyperplasia and prostatitis', Journal of Ethnopharmacology, pp. 2005. doi:10.1016/j.jep.2005.07.007 Traditional / reference
    https://doi.org/10.1016/j.jep.2005.07.007
  14. European Medicines Agency (HMPC) (2015) 'European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf Traditional / reference
    https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf
  15. Coulson, S., Rao, A., Beck, S.L., Steels, E., Gramotnev, H. and Vitetta, L (2013) 'A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation (containing Epilobium parviflorum) for the management of symptoms of benign prostatic hypertrophy', Complementary Therapies in Medicine. doi:10.1016/j.ctim.2013.01.007 Randomized trial
    https://doi.org/10.1016/j.ctim.2013.01.007
  1. Camilleri, E., Blundell, R., Baral, B., Karpinski, T.M. et al (2024) 'A brief overview of the medicinal and nutraceutical importance of Inonotus obliquus (chaga) mushrooms', Heliyon, 10(15), pp. e35638. doi:10.1016/j.heliyon.2024.e35638 Traditional / reference
    https://doi.org/10.1016/j.heliyon.2024.e35638
  2. Lu, Y., Jia, Y., Xue, Z., Li, N. et al (2021) 'Recent Developments in Inonotus obliquus (Chaga mushroom) Polysaccharides: Isolation, Structural Characteristics, Biological Activities and Application', Polymers (Basel), 13(9), pp. 1441. doi:10.3390/polym13091441 Traditional / reference
    https://doi.org/10.3390/polym13091441
  3. Kobus, Z., Krzywicka, M., Blicharz-Kania, A., Bosacka, A. et al (2024) 'Impact of Incorporating Dried Chaga Mushroom (Inonotus obliquus) into Gluten-Free Bread on Its Antioxidant and Sensory Characteristics', Molecules, 29(16), pp. 3801. doi:10.3390/molecules29163801 Preclinical
    https://doi.org/10.3390/molecules29163801
  4. Szychowski, K.A., Skora, B., Pomianek, T. and Gminski, J (2020) 'Inonotus obliquus - from folk medicine to clinical use', Journal of Traditional and Complementary Medicine, 11(4), pp. 293-302. doi:10.1016/j.jtcme.2020.08.003 Meta-analysis / review
    https://doi.org/10.1016/j.jtcme.2020.08.003
  5. Javed, S., Mitchell, K., Sidsworth, D., Sellers, S.L., Reutens-Hernandez, J., Massicotte, H.B., Egger, K.N., Lee, C.H. and Payne, G.W (2019) 'Inonotus obliquus attenuates histamine-induced microvascular inflammation', PLoS One, 14(8), pp. e0220776. doi:10.1371/journal.pone.0220776 Preclinical
    https://doi.org/10.1371/journal.pone.0220776
  6. Zou, C., Hou, Z., Bai, M., Guo, R., Lin, B., Wang, X., Huang, X. and Song, S (2020) 'Highly modified steroids from Inonotus obliquus', Organic & Biomolecular Chemistry, 18(20), pp. 3908-3916. doi:10.1039/d0ob00474j Preclinical
    https://doi.org/10.1039/d0ob00474j
  7. Zhong, X.H., Ren, K., Lu, S.J., Yang, S.Y. and Sun, D.Z (2009) 'Progress of research on Inonotus obliquus', Chinese Journal of Integrative Medicine, 15(2), pp. 156-160. doi:10.1007/s11655-009-0156-2 Meta-analysis / review
    https://doi.org/10.1007/s11655-009-0156-2
  8. Burmasova, M.A., Utebaeva, A.A., Sysoeva, E.V. and Sysoeva, M.A (2019) 'Melanins of Inonotus obliquus: bifidogenic and antioxidant properties', Biomolecules, 9(6), pp. 248. doi:10.3390/biom9060248 Preclinical
    https://doi.org/10.3390/biom9060248
  9. Sun, Y., Deng, X., Li, Z., Dong, Y., Jiang, W., Ma, Y., Zhou, W., Zhu, T., Wang, G., Liu, S. and Hu, B (2022) 'Polysaccharide derived from Inonotus obliquus inhibits lipopolysaccharide-induced acute endometritis in mice', American Journal of Translational Research, 14(11), pp. 8332-8342. Preclinical
    https://scholar.google.com/scholar?q=Polysaccharide%20derived%20from%20Inonotus%20obliquus%20inhibits%20lipopolysaccharide-induced%20acute%20endometritis%20in%20mice
  10. Ishfaq, P.M., Mishra, S., Mishra, A., Ahmad, Z., Gayen, S., Jain, S.K., Tripathi, S. and Mishra, S.K (2022) 'Inonotus obliquus aqueous extract prevents histopathological alterations in liver induced by environmental toxicant Microcystin', Current Research in Pharmacology and Drug Discovery, 3, pp. 100118. doi:10.1016/j.crphar.2022.100118 Preclinical
    https://doi.org/10.1016/j.crphar.2022.100118
  11. Peng, A., Liu, S., Fang, L., Zhu, Z., Zhou, Y., Yue, S., Ma, Z., Liu, X., Xue, S., Qiu, Y. and Qi, R (2022) 'Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis', European Journal of Pharmacology, 921, pp. 174841. doi:10.1016/j.ejphar.2022.174841 Preclinical
    https://doi.org/10.1016/j.ejphar.2022.174841
  12. Zhang, Y., Liu, Q., Sun, Y. and Jiang, J (2023) 'Inonotus obliquus sclerotia epidermis were different from internal tissues in compound composition, antioxidant activity, and associated fungi', FEMS Microbiology Letters, 370, pp. fnad126. doi:10.1093/femsle/fnad126 Preclinical
    https://doi.org/10.1093/femsle/fnad126
  13. Yu, S., Lai, Z., Xue, H., Zhu, J., Yue, G., Wang, J. and Jin, L.H (2024) 'Inonotus obliquus aqueous extract inhibits intestinal inflammation and insulin metabolism defects in Drosophila', Toxicology Mechanisms and Methods, 34(9), pp. 970-984. doi:10.1080/15376516.2024.2368795 Preclinical
    https://doi.org/10.1080/15376516.2024.2368795
  14. Wold, C.W. and Christopoulos, P. and Arias, M. and Dzovor, D.E. and Øynebråten, I. and Corthay, A. and Inngjerdingen, K.T (2024) 'Fungal polysaccharides from Inonotus obliquus are agonists for Toll-like receptors and induce macrophage anti-cancer activity', Communications Biology. doi:10.1038/s42003-024-05853-y Preclinical
    https://doi.org/10.1038/s42003-024-05853-y
  15. Li, J. and Qu, C. and Li, F. and Chen, Y. and Zheng, J. and Xiao, Y. and Jin, Q. and Jin, G. and Huang, X. and Jin, D (2021) 'Inonotus obliquus Polysaccharide Ameliorates Azoxymethane/Dextran Sulfate Sodium-Induced Colitis-Associated Cancer in Mice via Activation of the NLRP3 Inflammasome', Frontiers in Pharmacology. doi:10.3389/fphar.2020.621835 Preclinical
    https://doi.org/10.3389/fphar.2020.621835
  16. Wold, C.W. and Gerwick, W.H. and Wangensteen, H. and Inngjerdingen, K.T (2020) 'Bioactive triterpenoids and water-soluble melanin from Inonotus obliquus (Chaga) with immunomodulatory activity', Journal of Functional Foods. doi:10.1016/j.jff.2020.104025 Preclinical
    https://doi.org/10.1016/j.jff.2020.104025
  17. Kim, J. and Yang, S. and Hwang, A.Y. and Cho, H. and Hwang, K.T (2020) 'Composition of Triterpenoids in Inonotus obliquus and Their Anti-Proliferative Activity on Cancer Cell Lines', Molecules. doi:10.3390/molecules25184066 Preclinical
    https://doi.org/10.3390/molecules25184066
  18. Duru, K.C. and Kovaleva, E.G. and Данилова, И.Г. and Bijl, P.V.D (2019) 'The pharmacological potential and possible molecular mechanisms of action of Inonotus obliquus from preclinical studies', Phytotherapy Research. doi:10.1002/ptr.6384 Preclinical
    https://doi.org/10.1002/ptr.6384
  19. Hu, Y. and Teng, C. and Yu, S. and Wang, X. and Liang, J. and Bai, X. and Dong, L. and Song, T. and Yu, M. and Qu, J (2017) 'Inonotus obliquus polysaccharide regulates gut microbiota of chronic pancreatitis in mice', AMB Express. doi:10.1186/s13568-017-0341-1 Preclinical
    https://doi.org/10.1186/s13568-017-0341-1
  20. Chou, Y. and Kan, W. and Chang, C. and Peng, Y. and Wang, H. and Yu, W. and Cheng, Y. and Jhang, Y. and Liu, H. and Chuu, J (2016) 'Renal Protective Effects of Low Molecular Weight of Inonotus obliquus Polysaccharide (LIOP) on HFD/STZ-Induced Nephropathy in Mice', International Journal of Molecular Sciences. doi:10.3390/ijms17091535 Preclinical
    https://doi.org/10.3390/ijms17091535
  21. Arata, S. and Watanabe, J. and Maeda, M. and Yamamoto, M. and Matsuhashi, H. and Mochizuki, M. and Kagami, N. and Honda, K. and Inagaki, M (2016) 'Continuous intake of the Chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice', Heliyon. doi:10.1016/j.heliyon.2016.e00111 Preclinical
    https://doi.org/10.1016/j.heliyon.2016.e00111
  22. Lee, K.R. and Lee, J.S. and Kim, Y.R. and Song, I.G. and Hong, E.K (2014) 'Polysaccharide from Inonotus obliquus inhibits migration and invasion in B16-F10 cells by suppressing MMP-2 and MMP-9 via downregulation of NF-κB signaling pathway', Oncology Reports. doi:10.3892/or.2014.3103 Preclinical
    https://doi.org/10.3892/or.2014.3103
  23. Song, F. and Liu, Y. and Kong, X. and Chang, W. and Song, G (2013) 'Progress on Understanding the Anticancer Mechanisms of Medicinal Mushroom: Inonotus Obliquus', Asian Pacific Journal of Cancer Prevention. doi:10.7314/apjcp.2013.14.3.1571 Preclinical
    https://doi.org/10.7314/apjcp.2013.14.3.1571
  24. Gunjima, K. and Tomiyama, R. and Takakura, K. and Yamada, T. and Hashida, K. and Nakamura, Y. and Konishi, T. and Matsugo, S. and Hori, O (2013) '3,4‐Dihydroxybenzalacetone Protects Against Parkinson's Disease‐Related Neurotoxin 6‐OHDA Through Akt/Nrf2/Glutathione Pathway', Journal of Cellular Biochemistry. doi:10.1002/jcb.24643 Preclinical
    https://doi.org/10.1002/jcb.24643
  25. Geng, Y. and Lu, Z. and Huang, W. and Xu, H. and Shi, J. and Xu, Z (2013) 'Bioassay-Guided Isolation of DPP-4 Inhibitory Fractions from Extracts of Submerged Cultured of Inonotus obliquus', Molecules. doi:10.3390/molecules18011150 Preclinical
    https://doi.org/10.3390/molecules18011150
  26. Zhang, L. and Fan, C. and Liu, S. and Zang, Z. and Jiao, L. and Zhang, L (2011) 'Chemical composition and antitumor activity of polysaccharide from Inonotus obliquus', Journal of Medicinal Plants Research. doi:10.5897/jmpr.9000346 Preclinical
    https://doi.org/10.5897/jmpr.9000346
  27. Choi, S. and Hur, S.J. and An, C.S. and Jeon, Y.H. and Jeoung, Y.J. and Bak, J.P. and Lim, B.O (2010) 'Anti-Inflammatory Effects ofInonotus obliquusin Colitis Induced by Dextran Sodium Sulfate', Journal of Biomedicine and Biotechnology. doi:10.1155/2010/943516 Preclinical
    https://doi.org/10.1155/2010/943516
  28. Youn, M. and Kim, J. and Park, S. and Kim, Y. and Kim, S. and Lee, J.S. and Chai, K.Y. and Kim, H. and Cui, M. and So, H.S. and Kim, K. and Park, R (2008) 'Chaga mushroom (Inonotus obliquus ) induces G0/G1 arrest and apoptosis in human hepatoma HepG2 cells', World Journal of Gastroenterology. doi:10.3748/wjg.14.511 Preclinical
    https://doi.org/10.3748/wjg.14.511
  29. Nakajima, Y. and Sato, Y. and Konishi, T (2007) 'Antioxidant Small Phenolic Ingredients in Inonotus obliquus (persoon) Pilat (Chaga)', Chemical and Pharmaceutical Bulletin. doi:10.1248/cpb.55.1222 Preclinical
    https://doi.org/10.1248/cpb.55.1222
  30. Kim, H. and Yoon, D. and Kim, C. and Shrestha, B. and Chang, W. and Lim, S. and Lee, W. and Han, S. and Lee, J. and Lim, M. and Kim, G. and Choi, S. and Song, W.O. and Sung, J. and Hwang, K (2007) 'Ethanol Extract of Inonotus obliquus Inhibits Lipopolysaccharide-Induced Inflammation in RAW 264.7 Macrophage Cells', Journal of Medicinal Food. doi:10.1089/jmf.2006.156 Preclinical
    https://doi.org/10.1089/jmf.2006.156
  31. Mizuno, T. and Zhuang, C. and Abe, K. and Okamoto, H. and Kiho, T. and Ukai, S. and Leclerc, S. and Meijer, L (1999) 'Antitumor and Hypoglycemic Activities of Polysaccharides from the Sclerotia and Mycelia of Inonotus obliquus (Pers.: Fr.) Pil. (Aphyllophoromycetideae)', International journal of medicinal mushrooms. doi:10.1615/intjmedmushr.v1.i4.20 Preclinical
    https://doi.org/10.1615/intjmedmushr.v1.i4.20
  32. Su, L. and Xin, C. and Yang, J. and Dong, L. and Mei, H. and Dai, X. and Wang, Q (2022) 'A polysaccharide from Inonotus obliquus ameliorates intestinal barrier dysfunction in mice with type 2 diabetes mellitus', International Journal of Biological Macromolecules. doi:10.1016/j.ijbiomac.2022.06.071 Preclinical
    https://doi.org/10.1016/j.ijbiomac.2022.06.071
  33. Yang, M. and Hu, D. and Cui, Z. and Li, H. and Man, C. and Jiang, Y (2021) 'Lipid-Lowering Effects of Inonotus obliquus Polysaccharide In Vivo and In Vitro', Foods. doi:10.3390/foods10123085 Preclinical
    https://doi.org/10.3390/foods10123085
  34. Wang, J. and Hu, W. and Li, L. and Huang, X. and Liu, Y. and Wang, D. and Teng, L (2017) 'Antidiabetic activities of polysaccharides separated from Inonotus obliquus via the modulation of oxidative stress in mice with streptozotocin-induced diabetes', PLoS ONE. doi:10.1371/journal.pone.0180476 Preclinical
    https://doi.org/10.1371/journal.pone.0180476
  35. Giridharan, V.V. and Thandavarayan, R.A. and Konishi, T (2011) 'Amelioration of scopolamine induced cognitive dysfunction and oxidative stress by Inonotus obliquus– a medicinal mushroom', Food & Function. doi:10.1039/c1fo10037h Preclinical
    https://doi.org/10.1039/c1fo10037h
  36. Lee, J. and Hyun, C (2014) 'Insulin‐Sensitizing and Beneficial Lipid‐Metabolic Effects of the Water‐Soluble Melanin Complex Extracted from Inonotus obliquus', Phytotherapy Research. doi:10.1002/ptr.5131 Preclinical
    https://doi.org/10.1002/ptr.5131
  37. Kim, Y (2005) 'Immunomodulatory Activity of the Water Extract from Medicinal MushroomInonotus obliquus', Mycobiology. doi:10.4489/myco.2005.33.3.158 Preclinical
    https://doi.org/10.4489/myco.2005.33.3.158
  38. Géry, A., Dubreule, C., André, V., Rioult, J.P., Bouchart, V., Heutte, N., Eldin de Pécoulas, P., Krivomaz, T. and Garon, D (2018) 'Chaga (Inonotus obliquus), a future potential medicinal fungus in oncology? A chemical study and a comparison of the cytotoxicity against human lung adenocarcinoma cells (A549) and human bronchial epithelial cells (BEAS-2B)', 17(3), pp. 832--843. doi:10.1177/1534735418757912 Traditional / reference
    https://doi.org/10.1177/1534735418757912
  39. Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
    https://powo.science.kew.org
  40. Shashkina, M.Ya., Shashkin, P.N. and Sergeev, A.V (2006) 'Chemical and medicobiological properties of chaga', 40(10), pp. 560--568. Traditional / reference
    https://scholar.google.com/scholar?q=Chemical%20and%20medicobiological%20properties%20of%20chaga
  41. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.